High-dose erythropoietin has no effect on short-or long-term graft function following deceased donor kidney transplantation

Kidney International

Volumn 81, Issue 3, 2012, Pages 314-320

  Hafer, Carsten ^a   Becker, Thomas ^a   Kielstein, Jan T ^a   Bahlmann, Elisabeth ^a   Schwarz, Anke ^a   Grinzoff, Nikolai ^a   Drzymala, Daria ^a   Bonnard, Isabelle ^a   Richter, Nicolas ^a   Lehner, Frank ^a   Klempnauer, Juergen ^a   Haller, Hermann ^a   Traeder, Jana ^a   Fliser, Danilo ^b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

Author keywords

chronic renal disease; erythropoietin; graft survival; kidney transplantation

Indexed keywords

BASILIXIMAB; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; RECOMBINANT ERYTHROPOIETIN; STEROID; TACROLIMUS;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DELAYED GRAFT FUNCTION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG MEGADOSE; DRUG TOLERABILITY; FEMALE; GLOMERULUS FILTRATION RATE; GRAFT SURVIVAL; HISTOLOGY; HUMAN; INCIDENCE; KIDNEY ALLOGRAFT; KIDNEY BIOPSY; KIDNEY FUNCTION; KIDNEY GRAFT; KIDNEY GRAFT FUNCTION; KIDNEY TRANSPLANTATION; MALE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; SMALL INTESTINE PERFORATION; SURVIVAL;

EID: 84856708505     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2011.349     Document Type: Article

References (35)

1. Lappin TR, Maxwell AP, Johnston PG. EPO's alter ego: erythropoietin has multiple actions. Stem Cells 2002; 20: 485-492. (Pubitemid 35463061)
2. Sasaki R, Masuda S, Nagao M. Pleiotropic functions and tissue-specific expression of erythropoietin. News Physiol Sci 2001; 16: 110-113. (Pubitemid 33570297)
3. Goldman SA, Nedergaard M. Erythropoietin strikes a new cord. Nat Med 2002; 8: 785-787.
4. Juul SE, Yachnis AT, Christensen RD. Tissue distribution of erythropoietin and erythropoietin receptor in the developing human fetus. Early Hum Dev 1998; 52: 235-249. (Pubitemid 28548695)
5. Morishita E, Masuda S, Nagao M et al. Erythropoietin receptor is expressed in rat hippocampal and cerebral cortical neurons, and erythropoietin prevents in vitro glutamate-induced neuronal death. Neuroscience 1997; 76: 105-116. (Pubitemid 26407940)
6. Westenfelder C, Biddle DL, Baranowski RL. Human, rat, and mouse kidney cells express functional erythropoietin receptors. Kidney Int 1999; 55: 808-820. (Pubitemid 29100693)
7. Celik M, Gökmen N, Erbayraktar S et al. Erythropoietin prevents motor neuron apoptosis and neurologic disability in experimental spinal cord ischemic injury. Proc Natl Acad Sci USA 2002; 99: 2258-2263. (Pubitemid 34169048)
8. Chong ZZ, Kang JQ, Maiese K. Erythropoietin is a novel vascular protectant through activation of Akt1 and mitochondrial modulation of cysteine proteases. Circulation 2002; 106: 2973-2979. (Pubitemid 35424751)
9. Parsa CJ, Matsumoto A, Kim J et al. A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest 2003; 112: 999-1007. (Pubitemid 38056315)
10. Bahlmann FH, Song R, Boehm SM et al. Low-dose therapy with the longacting erythropoietin analogue darbepoetin alpha persistently activates endothelial Akt and attenuates progressive organ failure. Circulation 2004; 110: 1006-1012. (Pubitemid 39128626)
11. Digicaylioglu M, Lipton SA. Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kB signalling cascades. Nature 2001; 412: 641-647. (Pubitemid 32772276)
12. Matsumoto M, Makino Y, Tanaka T et al. Induction of renoprotective gene expression by cobalt ameliorates ischemic injury of the kidney in rats. J Am Soc Nephrol 2003; 14: 1825-1832. (Pubitemid 36750477)
13. Yang CW, Li C, Jung JY et al. Preconditioning with erythropoietin protects against subsequent ischemia-reperfusion injury in rat kidney. FASEB J 2003; 17: 1754-1755.
14. Sharples EJ, Patel N, Brown P et al. Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusion. J Am Soc Nephrol 2004; 15: 2115-2124. (Pubitemid 39031350)
15. Vesey DA, Cheung C, Pat B et al. Erythropoietin protects against ischaemic acute renal injury. Nephrol Dial Transplant 2004; 19: 348-355. (Pubitemid 38195983)
16. Patel NS, Sharples EJ, Cuzzocrea S et al. Pretreatment with EPO reduces the injury and dysfunction caused by ischemia/reperfusion in the mouse kidney in vivo. Kidney Int 2004; 66: 983-989. (Pubitemid 39121002)
17. Bahlmann FH, De Groot K, Spandau JM et al. Erythropoietin regulates endothelial progenitor cells. Blood 2004; 103: 921-926. (Pubitemid 38129551)
18. Walker SR, Yusuf SW, Wenham PW et al. Renal complications following endovascular repair of abdominal aortic aneurysms. J Endovasc Surg 1998; 5: 318-322. (Pubitemid 28565023)
19. Cherr GS, Hansen KJ. Renal complications with aortic surgery. Semin Vasc Surg 2001; 14: 245-254. (Pubitemid 33131295)
20. Gueler F, Gwinner W, Schwarz A et al. Long-term effects of acute ischemia and reperfusion injury. Kidney Int 2004; 66: 523-527. (Pubitemid 38981991)
21. Lieberthal W, Koh JS, Levine JS. Necrosis and apoptosis in acute renal failure. Semin Nephrol 1998; 18: 505-518. (Pubitemid 28430754)
22. Daemen MA, van 't Veer C, Denecker G et al. Inhibition of apoptosis induced by ischemia-reperfusion prevents inflammation. J Clin Invest 1999; 104: 541-549.
23. Gill JS, Tonelli M, Mix CH et al. The change in allograft function among long-term kidney transplant recipients. J Am Soc Nephrol 2003; 14: 1636-1642. (Pubitemid 36687067)
24. Dragun D, Hoff U, Park JK et al. Prolonged cold preservation augments vascular injury independent of renal transplant immunogenicity and function. Kidney Int 2001; 60: 1173-1181. (Pubitemid 34205818)
25. Hariharan S, Kasiske B, Matas A et al. Surrogate markers for long-term renal allograft survival. Am J Transplant 2004; 4: 1179-1183. (Pubitemid 38868612)
26. Schwarz A, Gwinner W, Hiss M et al. Safety and adequacy of renal transplant protocol biopsies. Am J Transplant 2005; 5: 1992-1996. (Pubitemid 41039876)
27. Gwinner W, Hinzmann K, Erdbruegger U et al. Acute tubular injury in protocol biopsies of renal grafts: prevalence, associated factors and effect on long-term function. Am J Transplant 2008; 8: 1684-1693.
28. Martinez F, Kamar N, Pallet N et al. For the NeoPDGF Study Investigators. High dose epoetin beta in the first weeks following renal transplantation and delayed graft function: results of the Neo-PDGF study. Am J Transplant 2010; 10: 1695-1700.
29. Endre ZH, Walker RJ, Pickering JW et al. Early intervention with erythropoietin does not affect the outcome of acute kidney injury (the EARLYARF trial). Kidney Int 2010; 77: 1020-1030.
30. Fliser D, De Groot K, Bahlmann FH et al. Mechanisms of disease: erythropoietin-an old hormone with a new mission? Nat Clin Pract Cardiovasc Med 2006; 3: 563-572. (Pubitemid 44445800)
31. Drueke TB, Locatelli F, Clyne N et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 335: 2071-2084. (Pubitemid 44749316)
32. Singh AK, Szczech L, Tang KL et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085-2098. (Pubitemid 44749317)
33. Pfeffer MA, Burdmann EA, Chen CY et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361: 2019-2032.
34. Ehrenreich H, Weissenborn K, Prange H et al. EPO Stroke Trial Group. Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke 2009; 40: e647-e656.
35. Najjar SS, Rao SV, Melloni C et al. Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: a randomized controlled trial. JAMA 2011; 305: 1863-1872.